<DOC>
	<DOCNO>NCT00070265</DOCNO>
	<brief_summary>Drugs use chemotherapy , capecitabine oxaliplatin , use different way stop tumor cell divide stop grow die . Giving capecitabine oxaliplatin surgery may shrink tumor remove . Giving capecitabine oxaliplatin surgery may kill remain tumor cell . This phase II trial study well capecitabine oxaliplatin work give surgery treat patient resectable liver metastasis secondary colorectal cancer</brief_summary>
	<brief_title>Neoadjuvant Adjuvant Capecitabine Oxaliplatin Treating Patients With Resectable Liver Metastases Secondary Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy toxicity neoadjuvant adjuvant capecitabine oxaliplatin patient resectable liver metastasis secondary colorectal cancer undergo surgery . II . Determine rate R0 resection patient treat regimen surgery . SECONDARY OBJECTIVES : I . Determine response rate patient treat regimen . II . Determine resectability subset patient define resectable preoperatively treated regimen . III . Determine improvement survival associate downstaging base metastatic colorectal prognostic score patient treat regimen . IV . Determine disease-free overall survival patient treat regimen . V. Correlate drug-specific biomarkers clinical response patient treat regimen . OUTLINE : This multicenter study . Neoadjuvant chemotherapy : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Surgery : Four six week completion chemotherapy , patient undergo surgical resection tumor . Adjuvant chemotherapy : Patients satisfactory response therapy receive 4 additional course oxaliplatin capecitabine surgery . Patients follow 4-6 week surgery , every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A maximum 80 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm hepatic colorectal metastasis percutaneous hepatic biopsy Imaging evidence liver metastasis CT helical scan Resectable disease , determine surgeon hepatic surgery expertise ( least 10 resection perform per year ) Resectable , define spar 2 adjacent liver segment adequate vascular inflow outflow hepatic remnant volume Minor resection ( less hemihepatectomy ) major resection ( hemihepatectomy extend hepatectomy ) allow Bilobar resection allow , include atypical resection No evidence extrahepatic disease chest xray CT scan chest , abdomen , pelvis Performance status Zubrod 01 WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great 2 mg/dL AST ALT great 300 IU/L No preexist chronic hepatic disease ( e.g. , chronic active hepatitis cirrhosis ) would preclude surgical resection metastasis Creatinine great 1.5 mg/dL Creatinine clearance 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except completely resect nonmelanoma skin cancer carcinoma situ cervix No preexisting grade 2 great peripheral neuropathy No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent biologic therapy No concurrent sargramostim ( GMCSF ) More 6 month since prior adjuvant fluorouracilbased chemotherapy No prior chemotherapy liver metastasis No prior oxaliplatin colorectal cancer No prior concurrent hepatic artery infusion chemotherapy metastatic disease No prior concurrent radiotherapy metastatic disease No prior concurrent radiofrequency ablation metastatic disease No prior concurrent cryotherapy/other ablative technique metastatic disease No concurrent investigational therapy No concurrent oral anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>